Drug Trial Radar · NCT07562087
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
722
Actual
Start
Mar 9, 2026
Primary completion
Oct 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP
- First posted
- May 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Conditions
- Lyme Disease
Interventions
TP-05 (lotilaner) Low DoseDrug
TP05 administered orally at the protocol-defined preventative dose.
TP-05 (lotilaner) High DoseDrug
TP05 administered orally at the protocol-defined preventative dose.
PlaceboDrug
Matching placebo administered orally according to the same dosing schedule as TP05.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Incidence of Treatment Emergent Adverse Events From BaselineTime frame: From day 1 through the end of study follow-up, an average of 15 months.
- Clinically Significant Changes From Baseline Chemistry Laboratory TestsTime frame: From day 1 through the end of study follow up, an average of 15 months.
- Clinically Significant Changes From Baseline Hematology Laboratory TestsTime frame: From day 1 through the end of study follow up, an average of 15 months.
- Clinically Significant Changes From Baseline Vital SignsTime frame: From day 1 through the end of study follow up, an average of 15 months.
- Clinically Significant Changes From Baseline Electrocardiograms (ECGs)Time frame: From day 1 through the end of study follow up, an average of 15 months.
- Clinically Significant Changes From Baseline Electrocardiograms (ECGs) MeasuresTime frame: From day 1 through the end of study follow up, an average of 15 months.
- Clinically Significant Changes From Baseline QTC IntervalTime frame: From day 1 through the end of study follow up, an average of 15 months.
- Clinically Significant Changes From Baseline QRS IntervalTime frame: From day 1 through the end of study follow up, an average of 15 months.
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Study Site
Pikesville, Maryland
Study Site
Brookline, Massachusetts
Study Site
Fall River, Massachusetts
Study Site
Minneapolis, Minnesota
Study Site
Marlboro, New Jersey
Study Site
Albany, New York
Study Site
Binghamton, New York
Study Site
Buffalo, New York
Study Site
East Syracuse, New York
Study Site
Middletown, New York
Study Site
New York, New York
Study Site
Rochester, New York
Study Site
Erie, Pennsylvania
Study Site
Hatboro, Pennsylvania
Study Site
Philadelphia, Pennsylvania
Study Site
Pittsburgh, Pennsylvania
Study Site
Pottstown, Pennsylvania
Study Site
West Chester, Pennsylvania
Study Site
Warwick, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.